** Drug developer Sangamo Therapeutics' shares SGMO.O fall 47.4% to $1.23 in extended trading
** SGMO said that Pfizer PFE.N terminated partnership to develop hemophilia A gene therapy
** Co's collaboration and license agreement with Pfizer will terminate, effective April 21, 2025
** In July, PFE announced positive results from a late-stage study of therapy
** SGMO said it plans to explore all options to commercialize the hemophilia A gene therapy, including seeking a new partner
** Up to Monday's close, SGMO is up 330.7% YTD
(Reporting by Rishi Kant in Bengaluru)
((Rishi.Kant@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。